Lv5
1000 积分 2023-06-29 加入
A way to resource is a big power to success.
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
13天前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
16天前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
16天前
已完结
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
17天前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
22天前
已完结
Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials
1个月前
已完结
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
1个月前
已完结
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial
1个月前
已完结
Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study
1个月前
已完结
Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT
1个月前
已完结
皖公网安备34019202002308
